OPKO Health Inc. Common Stock (OPK)

FairStock Score: 36/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earning power and a margin of safety. OPKO Health does not yet fit that description. It operates diagnostics and pharmaceutical segments, but the filed record shows revenue falling from $863.5 million in FY2023 to $713.1 million in FY2024 and $606.9 million in FY2025. Net losses were $188.9 million, $53.2 million, and $225.7 million in those same years. In the latest fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $163.6 million and net loss was $8.4 million, better than fiscal Q1 2026, quarter ended 2026-03-31, when net loss was $54.8 million. Still, trailing free cash flow is -$134.0 million, a -13.6% FCF yield. At the close on 2026-10-13, price was $1.32 and market cap was $985.2 million. FairStock shows P/B 0.83, so the market pays less than book value, and P/E -18.86 because there are no positive earnings. But cheap assets can be a trap when cash is going out the door; FairStock's Altman Z-Score of -0.61 and ROE of -5.88% reinforce caution. EV/EBITDA of 19.72 is not a bargain for a business with declining annual revenue. The drug candidates are in Phase 1, so any moat is speculative. I would want stable revenue, positive free cash flow, and a stronger balance sheet before calling this a value opportunity. A 4/9 Piotroski score and no Lynch category because of four straight loss years tell me the odds are not yet favorable.

In plain English: OPKO Health is a healthcare company that does laboratory testing and develops experimental drugs. It has been losing money, and annual revenue fell from fiscal 2023 to fiscal 2025. At $1.32, the stock looks cheap compared with its accounting value, but the business is weak and burning cash, so it is not clearly a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q4 2025 10-K (period ended 2025-12-31) · fiscal Q3 2025 10-K (period ended 2025-09-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer